Imaging Techniques in Alzheimer’s Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring
Open accessThe DOI matches its Crossref record; 228 of the 232 references it cites were found in a registry or an index.
Abstract
Background. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting many individuals worldwide with no effective treatment to date. AD is characterized by the formation of senile plaques and neurofibrillary tangles, followed by neurodegeneration, which leads to cognitive decline and eventually death. Introduction. In AD, pathological changes occur many years before disease onset. Since disease-modifying therapies may be the most beneficial in the early stages of AD, biomarkers for the early diagnosis and longitudinal monitoring of disease progression are essential. Multiple imaging techniques with associated biomarkers are used to identify and monitor AD. Aim. In this review, we discuss the contemporary early diagnosis and longitudinal monitoring of AD with imaging techniques regarding their diagnostic utility, benefits and limitations. Additionally, novel techniques, applications and biomarkers for AD research are assessed. Findings. Reduced hippocampal volume is a biomarker for neurodegeneration, but atrophy is not an AD-specific measure. Hypometabolism in temporoparietal regions is seen as a biomarker for AD. However, glucose uptake reflects astrocyte function rather than neuronal function. Amyloid-β (Aβ) is the earliest hallmark of AD and can be measured with positron emission tomography (PET), but Aβ accumulation stagnates as disease progresses. Therefore, Aβ may not be a suitable biomarker for monitoring disease progression. The measurement of tau accumulation with PET radiotracers exhibited promising results in both early diagnosis and longitudinal monitoring, but large-scale validation of these radiotracers is required. The implementation of new processing techniques, applications of other imaging techniques and novel biomarkers can contribute to understanding AD and finding a cure. Conclusions. Several biomarkers are proposed for the early diagnosis and longitudinal monitoring of AD with imaging techniques, but all these biomarkers have their limitations regarding specificity, reliability and sensitivity. Future perspectives. Future research should focus on expanding the employment of imaging techniques and identifying novel biomarkers that reflect AD pathology in the earliest stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The Alzheimer’s disease continuum with corresponding pathological changes, biomarkers and clinical diagnosis. Figure adapted from Yoshiyama et al. [21].](https://figures.cochat.ai/paper-figures/5ed93dc48917473ca30ad0e7a8a74987/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-1.jpg)
![Figure 6 Tau spreading pattern in each Braak stage. Spreading pattern of tau throughout the brain from Braak stage I-II to stage III-IV (limbic regions) and stage V-VI (isocortical areas). Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/f800c1b6e6e24d13ba3b3f4e8509a14d/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-6.jpg)


![Figure 4 Accumulation of amyloid-β in AD. Figure adapted from Patterson et al. [89] and created with www.BioRender.com (accessed on 16 November 2020).](https://figures.cochat.ai/paper-figures/49d3fbddca5e428ea039b5bd152e68a0/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-4.jpg)


![Figure 8 Spreading pattern of amyloid-β accumulation throughout the brain. Amyloid-β accumulation starts in frontal areas and spreads to other regions as disease progresses, leading to a plateau in amyloid-β as disease progresses. Figure adapted from Goedert [145] and created with www.BioRender.com (accessed on 11 February 2021).](https://figures.cochat.ai/paper-figures/d4b1f0c188954fbdb7a6946c934ad246/imaging-techniques-in-alzheimers-disease-a-review-of-applications-in-early-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, sMRI and (18FDG)-PET indicate neurodegeneration or neuronal injury in the AT(N) framework with limitations in specifically diagnosing AD.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They cannot accurately differentiate AD from other neurodegenerative diseases with similar pathologies, such as frontotemporal degeneration and TDP-43 proteinopathies with medial temporal lobe atrophy.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [370]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD diagnosis relies on detecting amyloid and tau pathology via positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) analysis [8,9,10].”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“, reporting decreased metabolism in the same two medial prefrontal regions [3,157] Altogether, these findings highlight the potential of FDG-PET for the longitudinal monitoring of AD progression.”
BackgroundInfluentialThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Huang, D., Swanson, E. A., Lin, C. P., Schuman, J. S., Stinson, W. G., Chang, W., Hee, M. R., Flotte, T., Gregory, K., Puliafito, C. A., et al. (1991) · Science · doi:10.1126/science.1957169 · Cited by 13,788
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676 · cited 7×
“Currently, two distinct biomarkers are used to assess Aβ pathology: the concentration of Aβ42 in the CSF and 2.3.2.”
MethodInfluentialAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“leading to the formation of senile plaques [7,20,82,83].”
BackgroundFunctional connectivity in the resting brain: a network analysis of the default mode hypothesis
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135058100 · Cited by 6,358
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“All other disease characteristics, such as the formation of NFTs out of hyperphosphorylated tau, and neurodegeneration, are seen a result of this accumulation [12,83,88].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 2×
“This statement is further underlined by the hypothetical model of dynamic biomarkers [77,78].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Pathogenesis of Alzheimer’s Disease
Rostagno, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010107 · Cited by 383
“The manuscript discussed the value of using radiotracers to assess hippocampal volume, hypometabolism in temporoparietal brain regions, and Aβ and Tau accumulation, emphasizing their limitations regarding specificity, reliability, and sensitivity [18].”
BackgroundThe Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need
Wang, S., Jiang, Y., Yang, A., Meng, F., & Zhang, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.1071 · Cited by 269
Kale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
Alsubaie, M. G., Luo, S., & Shaukat, K. (2024) · Machine Learning and Knowledge Extraction · doi:10.3390/make6010024 · Cited by 185
Neuroimaging Modalities in Alzheimer’s Disease: Diagnosis and Clinical Features
Kim, J., Jeong, M., Stiles, W. R., & Choi, H. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116079 · Cited by 124
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Halkiopoulos, C., Gkintoni, E., Aroutzidis, A., & Antonopoulou, H. (2025) · Diagnostics · doi:10.3390/diagnostics15040456 · Cited by 121
A transformer-based unified multimodal framework for Alzheimer's disease assessment
Yu, Q., Ma, Q., Da, L., Li, J., Wang, M., Xu, A., Li, Z., & Li, W. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108979 · Cited by 111
Sequeira-Antunes, B., & Ferreira, H. A. (2023) · Biomedicines · doi:10.3390/biomedicines11041051 · Cited by 107
Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer’s Disease
Pradeepkiran, J. A., Baig, J., Islam, M. A., Kshirsagar, S., & Reddy, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0286 · Cited by 102
Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
Habashi, M., Vutla, S., Tripathi, K. K., Senapati, S., Chauhan, P. S., Haviv‐Chesner, A., Richman, M., Mohand, S.-A., Dumulon‐Perreault, V., Mulamreddy, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210766119 · Cited by 88
“For improved patient selection and accurate monitoring of response to treatment, a PET/CT imaging agent targeting soluble A β oligomers is acutely needed for early AD diagnosis (22).”
What Is the Role of Explainability in Medical Artificial Intelligence? A Case-Based Approach
Hildt, E. (2025) · Bioengineering · doi:10.3390/bioengineering12040375 · Cited by 83
“A broad spectrum of approaches exists for detecting AD in its early stages, including brain imaging techniques such as magnetic resonance imaging (MRI) or positron emission tomography (PET) [57,58].”
Explainable Artificial Intelligence in Neuroimaging of Alzheimer’s Disease
Taiyeb Khosroshahi, M., Morsali, S., Gharakhanlou, S., Motamedi, A., Hassanbaghlou, S., Vahedi, H., Pedrammehr, S., Kabir, H. M. D., & Jafarizadeh, A. (2025) · Diagnostics · doi:10.3390/diagnostics15050612 · Cited by 68
“…function, including the ability to correlate abnormal activity with areas of amyloid deposition and explore functional connectivity between brain networks, yet it is unable to detect A β plaques and NFTs [141], is sensitive to head motion [142], is costly, and has restricted temporal resolution.”
Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers
Dang, C., Wang, Y., Li, Q., & Lu, Y. (2023) · Psychoradiology · doi:10.1093/psyrad/kkad009 · Cited by 67
Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations
Juganavar, A., Joshi, A., & Shegekar, T. (2023) · Cureus · doi:10.7759/cureus.44937 · Cited by 68
“Advanced neuroimaging methods, such as targeted PET scans, can be costly and require specialised equipment and skills [56].”
BackgroundNeuroimaging in Alzheimer's Disease for Early Diagnosis: A Comprehensive Review
Aramadaka, S., Mannam, R., Narayanan, R. S., Bansal, A., Yanamaladoddi, V. R., Sarvepalli, S. S., & Vemula, S. L. (2023) · Cureus · doi:10.7759/cureus.38544 · Cited by 64
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
Balestri, W., Sharma, R., da Silva, V. A., Bobotis, B. C., Curle, A. J., Kothakota, V., Kalantarnia, F., Hangad, M. V., Hoorfar, M., Jones, J. L., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03024-8 · Cited by 56
Puranik, N., & Song, M. (2024) · Molecules · doi:10.3390/molecules29235744 · Cited by 55
“Structural MRI shows hippocampal loss, whilst 18FDG-PET shows diminished glucose uptake may also be relevant to GLU-mediated synaptic deficit [167].”
Small-molecule theranostics in Alzheimer's disease
Sarabia‐Vallejo, Á., López‐Alvarado, P., & Menéndez, J. C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115382 · Cited by 52
Classification of Alzheimer’s disease stages from magnetic resonance images using deep learning
Mora-Rubio, A., Bravo-Ortíz, M. A., Arredondo, S., Saborit-Torres, J. M., Ruz, G. A., & Tabares-Soto, R. (2023) · PeerJ Computer Science · doi:10.7717/peerj-cs.1490 · Cited by 52
“Medical imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, are utilized by specialists to evaluate the morphological changes in the brain caused by AD ( van Oostveen & de Lange, 2021 ).”
MethodDiagnostic Blood Biomarkers in Alzheimer’s Disease
Park, J.-E., Gunasekaran, T. I., Cho, Y. H., Choi, S., Song, M., Cho, S. H., Kim, J., Song, H., Choi, K. Y., Lee, J. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010169 · Cited by 51
“The limitations of currently available MRI-based approaches are evident [6].”
BackgroundMethodInfluentialShobeiri, P., Alilou, S., Jaberinezhad, M., Zare, F., Karimi, N., Maleki, S., Teixeira, A. L., Perry, G. L., & Rezaei, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281784 · Cited by 50
Mirkin, S., & Albensi, B. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1094233 · Cited by 46
Shang, Y., Yi, X., Xiang, D., & Zhou, L. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s522736 · Cited by 46
Chen, Y., Qi, Y., Hu, Y., Qiu, X., Qiu, T., Li, S., Liu, M., Jia, Q., Sun, B., Liu, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14361 · Cited by 40
Senapati, S., Tripathi, K. K., Awad, K., & Rahimipour, S. (2024) · Small · doi:10.1002/smll.202311670 · Cited by 39
Structural MRI Texture Analysis for Detecting Alzheimer’s Disease
Silva, J., Bispo, B. C., Rodrigues, P. M., & Initiative, A. D. N. (2023) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-023-00787-y · Cited by 39
“The imaging modalities are currently focusing on the identification of amyloid deposition or neurodegeneration, e.g., structural MRI allows the computation of atrophy and changes measurements in tissue [4].”
BackgroundXi, M., Sun, T., Chai, S., Xie, M., Chen, S., Deng, L., Du, K., Shen, R., & Sun, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114170 · Cited by 37
Future of Alzheimer’s Disease: Nanotechnology-Based Diagnostics and Therapeutic Approach
Agraharam, G., Saravanan, N., Girigoswami, A., & Girigoswami, K. (2022) · BioNanoScience · doi:10.1007/s12668-022-00998-8 · Cited by 37
Transcranial Magnetic Stimulation as a Diagnostic and Therapeutic Tool in Various Types of Dementia
Antczak, J. M., Rusin, G., & Słowik, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132875 · Cited by 36
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Odusami, M., Damaševičius, R., Belousovienė, E., & Maskeliūnas, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34402 · Cited by 34
“Current diagnostic approaches for AD begin to focus primarily on modern imaging modalities, with a distinct focus on detecting either amyloid deposition or neurodegeneration [80].”
BackgroundLi, Y., Zhou, K., Zhang, X., Zhao, H., Wang, X., Dong, R., Wang, Y., Chen, B., Yan, X., Dai, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01503 · Cited by 34
A dual-functional fluorescence probe for detection of Aβ aggregates and hydroxyl radicals
An, Y., Luo, X., Wei, S., Lv, J., Gao, J., Li, X., Yang, M., Luo, J., Wu, Y., Wei, G., et al. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134653 · Cited by 34
Exploring Alzheimer's disease treatment: Established therapies and novel strategies for future care
Soni, U., Singh, K., Jain, D., & Pujari, R. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177520 · Cited by 33
Nutrients and amyloid β status in the brain: A narrative review
Díaz, G., Lengelé, L., Sourdet, S., Soriano, G., & Barreto, P. D. S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101728 · Cited by 33
Alzheimer's disease: Potential pathogenesis and imaging findings
Zhang, Y., Zhang, C., Liu, J., & Shao, H. (2023) · View · doi:10.1002/viw.20230025 · Cited by 33
Charting brain morphology in international healthy and neurological populations
Zhuo, Z., Chai, L., Wang, Y., Gao, P., Xu, X., Ai, L., Ao, F., Bai, Y., Bai, Y., Cole, J. H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02144-5 · Cited by 33
“Fourth, we performed resampling of cases aged below 18 years to evaluate the sensitivity of peak age estimates to varying sample sizes (ranging from 208 to 2,084) in this age group (Supplementary Results 4 and Extended Data Fig.”
InfluentialA new ITO-based Aβ42 biosensor for early detection of Alzheimer's disease
Altay, D. N., Yağar, H., & Özcan, H. M. (2023) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2023.108501 · Cited by 32
Yasmin, A., Jha, R., Passi, A., Saha, P., Goyal, J., Jindal, S., & Goyal, K. (2025) · Biomarkers · doi:10.1080/1354750x.2025.2591717 · Cited by 31
Cerebrospinal fluid: A specific biofluid for the biosensing of Alzheimer's diseases biomarkers
Mirzaie, A., Nasrollahpour, H., Khalilzadeh, B., Jamali, A. A., Spiteri, R. J., Yousefi, H., Işıldak, İ., & Rahbarghazi, R. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117174 · Cited by 31
A comprehensive multi-omics analysis reveals unique signatures to predict Alzheimer’s disease
Vacher, M. A., Cánovas, R., Laws, S. M., & Doecke, J. D. (2024) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2024.1390607 · Cited by 30
Non-Invasive Retinal Biomarkers for Early Diagnosis of Alzheimer’s Disease
Kaštelan, S., Antunica, A. G., Puzović, V., Pavičić, A. D., Čanović, S., Kovačević, P., Vučemilović, P. A. F., & Konjevoda, S. (2025) · Biomedicines · doi:10.3390/biomedicines13020283 · Cited by 27
“Studies have identified several correlations between AD and ocular changes, including the accumulation of A β in the retina and lens, retinal vascular abnormalities, and retinal nerve damage, evidenced by the thinning of the RNFL [47–50].”
Chen, Z., Chen, K., Li, Y., Geng, D., Li, X., Liang, X., Lu, H., Ding, S., Xiao, Z., Ma, X., et al. (2023) · Human Brain Mapping · doi:10.1002/hbm.26529 · Cited by 27
“…progressive decline of cognitive functions including episodic memory, language facilities, spatial processing ability and executive functions, and accumulation of abnormal proteins (A β and tau) in the brain pathologically (Albert et al., 2011; Braak & Braak, 1991; van Oostveen & de Lange, 2021).”
Daily, K. P., Badr, A., Eltobgy, M. M., Estfanous, S. Z. K., Whitham, O. D., Tan, M. H., Carafice, C., Krause, K., McNamara, A. J., Hamilton, K., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01390-2 · Cited by 27
“The temporal lobe is often the location where the characteristic spread of AD pathology including Aβ plaques starts [26].”
BackgroundInnovations in noninvasive sensory stimulation treatments to combat Alzheimer’s disease
Park, J. M., & Tsai, L. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003046 · Cited by 27
“Breakthroughs in diagnostic tools, including advanced imaging techniques and disease biomarkers [6,71–73], enable earlier and more accurate detection of AD long before the appearance of cognitive symptoms.”
Cheng, J., Wang, H., Wei, S., Mei, J., Liu, F., & Zhang, G. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108000 · Cited by 26
Couvy‐Duchesne, B., Frouin, V., Bouteloup, V., Koussis, N. C., Sidorenko, J., Jiang, J., Wink, A. M., Lorenzini, L., Barkhof, F., Trollor, J. N., et al. (2025) · Human Brain Mapping · doi:10.1002/hbm.70089 · Cited by 26
Doke, R. R., Lamkhade, G., Vinchurkar, K., & Singh, S. K. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00457 · Cited by 26
Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis
Sowmiya, S., Ls, D., Rajendran, P., Harikrishnan, N., & Ankul Singh, S. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.11.004 · Cited by 25
Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 25
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
“FDG-PET shows that GLUT1 levels are substantially diminished in brain micro-vessels in AD (19, 38), Moreover, imaging has revealed that patients with MCI have reduced glucose uptake in multiple brain areas prior to any apparent neurodegenerative changes, brain atrophy or conversion to AD (39, 40).”
BackgroundImproving Alzheimer’s disease classification using novel rewards in deep reinforcement learning
Hatami, M., Yaghmaee, F., & Ebrahimpour, R. (2024) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2024.106920 · Cited by 24
Habibi, F., Ghaderkhani, S., Shokoohi, M., Banari, T., Morsali, M., Abadi, R. N. S., & Kiamehr, H. (2025) · AI and Ethics · doi:10.1007/s43681-025-00673-0 · Cited by 23
“AD is marked by progressive brain changes, including amyloid plaques, neurofibrillary tangles, and cortical atrophy, which are difficult to detect in the early stages using conventional diagnostic methods [84 ].”
Shah, S., & Shah, M. (2024) · Advances in Biomarker Sciences and Technology · doi:10.1016/j.abst.2024.08.004 · Cited by 22
Liu, J., Xu, Y., Liu, Y., Luo, H., Huang, W., & Yao, L. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3482001 · Cited by 22
Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
Yang, J., Liang, L., Wei, Y., Liu, Y., Li, X., Huang, J., Zhang, Z., Li, L., & Deng, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1297028 · Cited by 21
“Studies have illustrated that brain atrophy severity correlates with AD progression (7).”
BackgroundNavigating the Alzheimer’s Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics
Abiad, E. E., Al-Kuwari, A., Al-Aani, U., Jaidah, Y. A., & Châari, A. (2024) · Cells · doi:10.3390/cells13221901 · Cited by 21
“A key indicator of disease progression is Amyloid Beta (A β ) aggregation, which results from incorrect cleavage of Amyloid Precursor Protein (APP) [6].”
Orzyłowska, A., & Oakden, W. (2021) · Brain Sciences · doi:10.3390/brainsci12010053 · Cited by 20
“The other drawbacks of PET imaging in everyday practice are cost and availability [34,35].”
BackgroundMethodInfluentialYuan, C., Duan, J., Tustison, N. J., Xu, K., Hubbard, R. A., & Linn, K. A. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00323 · Cited by 20
“Imaging Neuroscience, Volume 2, 2024 brain structure or function that occur as AD progresses ( van Oostveen & de Lange, 2021).”
Corti, M., Bonizzoni, F., & Antonietti, P. F. (2024) · Journal of Scientific Computing · doi:10.1007/s10915-024-02581-7 · Cited by 19
“A mathematical description of the spreading at the macroscopic level can be a useful tool in clinical practice, where the use of positron emission tomography imaging (PET) is often considered too invasive and expensive [4].”
InfluentialJunceda, S., Cruz‐Alonso, M., Fernández, B., Pereiro, R., Martínez‐Pinilla, E., & Navarro, A. (2024) · Biomolecules · doi:10.3390/biom14030295 · Cited by 18
“For example, post mortem Fe testing has the advantage of providing direct measurements of this ion in the brain, which is currently not possible in living people despite the improvements in magnetic resonance imaging (MRI) measurements [26,28].”
BackgroundNallapu, B. T., Initiative, T. A. D. N., Petersen, K. K., Lipton, R. B., Davatzikos, C. A., & Ezzati, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230620 · Cited by 17
Novel techniques for early diagnosis and monitoring of Alzheimer’s disease
Parul, P., Singh, A. K., & Shukla, S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2415985 · Cited by 17
“Advanced diagnostic techniques, such as positron emission tomography (PET) scans and magnetic resonance imaging (MRI), can be expensive and may not be readily accessible to all individuals, limiting widespread early detection efforts [43].”
Biomarkers Unveiling Neurodegeneration: Keys to Progression and Therapeutic Insights
Das, J., Bhui, U., Chowdhary, S., Sarkar, S., Ghoshal, I. K., Nayak, S., Bishayee, R., Khurana, N., Kumar, B., & Sharma, N. (2025) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.20250179 · Cited by 17
Advance and Prospect of Positron Emission Tomography in Alzheimer’s disease research
Wang, Y., Liao, W., Wang, L., Li, J., Huang, D., Cheng, W., Tian, J., & Luan, P. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03081-2 · Cited by 17
Thaker, A. A., McConnell, B. V., Rogers, D., Carlson, N. E., Coughlan, C. M., Jensen, A. M., Lopez‐Paniagua, D., Holden, S. K., Pressman, P., Pelak, V. S., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.06.026 · Cited by 16
Image processing: an early detection tool for Alzheimer’s disease
Ballav, S., Biswas, B., Dey, S., Sahu, V. K., & Basu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95539-3.00001-6 · Cited by 17
Amyloid detection in neurodegenerative diseases using MOFs
Maru, K., Singh, A., Jangir, R., & Jangir, K. K. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00373j · Cited by 16
Xu, Y., Xu, M., Zhou, C., Sun, L., Cai, W., & Li, X. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112443 · Cited by 16
“The hippocampus plays a crucial role in AD, characterized by the progressive loss of cholinergic neurons within the hippocampal and cortical areas, atrophy, abnormal neurotransmission, synaptic loss, and neurodegeneration (van Oostveen and de Lange, 2021).”
BackgroundRathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16
Abedi, A., Foroutan, T., Shalmani, L. M., & Dargahi, L. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111795 · Cited by 16
Li, J., Li, X., Chen, F., Li, W., Chen, J., & Zhang, B. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0098 · Cited by 16
Entropy and Fractal Analysis of EEG Signals for Early Detection of Alzheimer's Dementia
Hadiyoso, S., Wijayanto, I., & Humairani, A. (2023) · Traitement du signal · doi:10.18280/ts.400435 · Cited by 15
“Medical imaging techniques, including MRI, CT-Scan, and FDG-PET [10, 11], whilst sensitive to AD, are costly and typically available only in central hospitals [3].”
BackgroundGivian, H., & Calbimonte, J.-P. (2024) · IEEE Access · doi:10.1109/access.2024.3438081 · Cited by 15
“The implementation of these new processing techniques based on signal or image applications and novel biomarkers can contribute to understanding AD and finding a cure [20].”
BackgroundElectrochemical biosensors for early detection of Alzheimer’s disease
Jakhonkulovna, S. M., Kamolovna, G. B., Zokirov, M., Tajimuratovna, B. U., Yumashev, A., SHICHIYAKH, R. A., Safarova, N. I., Nusratovna, A. N., Esanmuradova, N., Karimbaevna, T. M., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120278 · Cited by 17
Individualized Assessment of Brain Aβ Deposition With fMRI Using Deep Learning
Li, C., Liu, M., Xia, J., Mei, L., Yang, Q., Shi, F., Zhang, H., & Shen, D. G. (2023) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2023.3306460 · Cited by 15
“The A β -PET grade prediction was solely based on graph convolution networks (GCNs), while the SUVR predictions utilized both GCNs and random forest (RF). could evaluate demyelination and neurodegeneration caused by AD [12] although it was not adequately sensitive to early stages of AD [13], [14].”
MethodKou, X., Hu, C., Pang, Z., Zhang, X., Wang, H., Shen, R., & Yang, A. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341818 · Cited by 15
Dendritic spines and their role in the pathogenesis of neurodevelopmental and neurological disorders
Akhgari, A., Michel, T. M., & Vafaee, M. S. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0151 · Cited by 15
“In the so-called amyloid cascade hypothesis, abnormal deposition of amyloid-β protein contributes to the formation of senile extracellular plaques and intracellular neuro fi brillary tangles composed of hyperphosphorylated tau aggregates (van Oostveen and De Lange 2021).”
BackgroundPromising Natural Remedies for Alzheimer’s Disease Therapy
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2025) · Molecules · doi:10.3390/molecules30040922 · Cited by 14
“The atrophy of brain areas and the cognitive decline that characterizes AD are caused by the death of neurons.”
An Overview of New and Emerging Technologies for Early Diagnosis of Alzheimer Disease
Wells, C., & Horton, J. (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.330 · Cited by 14
Alzheimer's disease, a metabolic disorder: Clinical advances and basic model studies (Review)
Zhou, S., Tu, L., Chen, W., Yan, G., Guo, H., Wang, X., Hu, Q., Liu, H., & Li, F. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12351 · Cited by 14
“Elevated VAT is associated with cortical thinning, particularly with decreased hippocampal volume (52).”
BackgroundCorti, M. (2024) · Brain Multiphysics · doi:10.1016/j.brain.2024.100098 · Cited by 13
“025 and simulate up to T = 40 years to have a complete sensitivity analysis over a time interval larger than the typical scales of Alzheimer’s disease [4].”
BackgroundWei, Y., Kung, Y., Lin, C., Yeh, C., Chen, P., Huang, W., Shyu, Y., Lin, C., & Chen, C. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03049-w · Cited by 13
Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies—A Narrative Review
Capatina, T.-F., Oatu, A., Babasan, C., & Trifu, S. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094285 · Cited by 13
Bonarota, S., Caruso, G., Domenico, C. D., Sperati, S., Tamigi, F. M., Giulietti, G., Giove, F., Caltagirone, C., & Serra, L. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121264 · Cited by 13
“…are of paramount importance for the acquisition of precise and reproducible measurements, thereby facilitating early diagnosis and prognostic assessment of AD (Bozzali et al., 2016; Abrigo et al., 2019; Leocadi et al., 2020; van Oostveen and de Lange, 2021; Chiappiniello et al., 2021).”
Restoring glucose metabolism in Alzheimer's disease by targeting integrated stress response
Sun, H., Guo, S., Jin, H., Ding, L., Chen, Y., Zhang, Y., He, K., Huang, Q., Gu, J., Chen, S., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00618 · Cited by 13
Retinal Microstructural and Microvascular Changes in Alzheimer Disease: A Review
Ordoñez, M. A. O., Smith, R. C., Yiu, G. C., & Liu, Y. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000549 · Cited by 12
Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases
Tong, J., Chen, B., Tan, P. W., Kurpiewski, S., & Cai, Z. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1062432 · Cited by 12
Verovnik, B., Khachatryan, E., Šuput, D., & Hulle, M. M. V. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12991 · Cited by 12
Assessment of individual retinal layer thickness and vascular changes in Alzheimer’s disease
Zabel, P., Przekoracka‐Krawczyk, A., Jaworski, D., Zabel, K., Suwała, K., Gębska‐Tołoczko, M., Kucharski, R., & Kałuzny, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-02377-1 · Cited by 11
Wang, W., Du, R., Wang, Z., Luo, X., Zhao, H., Luan, P., Ouyang, J., & Liu, S. (2023) · Brain‐X · doi:10.1002/brx2.35 · Cited by 11
Corti, M., Bonizzoni, F., Antonietti, P. F., & Quarteroni, A. M. (2023) · ESAIM Mathematical Modelling and Numerical Analysis · doi:10.1051/m2an/2023095 · Cited by 11
“We attribute this inconsistency to the atrophy of the region, which can be observed in the MRI images around the ventricles, and which is typical of AD [4].”
BackgroundMethodFully automated whole brain segmentation from rat MRI scans with a convolutional neural network
Porter, V. A., Hobson, B. A., Foster, B. H., Lein, P. J., & Chaudhari, A. J. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110078 · Cited by 11
Malu, G., Uday, N., Sherly, E., Abraham, A., & Bodhey, N. K. (2024) · IEEE Access · doi:10.1109/access.2024.3408311 · Cited by 11
“The role of FDG PET in monitoring AD is limited, and amyloid PET scans for detecting amyloid plaques may be more promising [37], [38]; However, this process may be slow, require monitoring for years, and disease progression may plateau over time.”
Zarovniaeva, V., Anwar, S., Kazmi, S., Perez, K. J., Sandhu, S., & Mohammed, L. (2025) · Cureus · doi:10.7759/cureus.77781 · Cited by 11
Risacher, S. L. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001509 · Cited by 11
Bahman, M., Hosseini, M. R. M., & Jameie, S. B. (2026) · RSC Advances · doi:10.1039/d5ra07458d · Cited by 10
“90,91 From a therapeutic perspective, A b detection is essential for evaluating the e ffi cacy of emerging anti-A b therapies.”
Metadata
- Authors
- van Oostveen, W. M., & de Lange, E. C. M.
- Affiliations
- Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre of Drug Research, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-20
- Volume
- 22
- Issue
- 4
- Pages
- 2110
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7924338
- OpenAlex
- W3131910442
- Cited by
- 297
- References
- 232
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 75 · 2023: 55 · 2022: 24 · 2021: 11
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, neuroimaging biomarkers, early diagnosis, longitudinal disease monitoring, amyloid PET, hippocampal atrophy, hypometabolism, glucose uptake, neurodegeneration, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Amyloid, Humans, Longitudinal Studies, Biomarkers, Early Diagnosis, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.